Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

Ann Oncol. 2008 Mar;19(3):595-7. doi: 10.1093/annonc/mdn021. Epub 2008 Feb 13.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / therapy*
  • Capecitabine
  • Carcinoma, Ductal / genetics*
  • Carcinoma, Ductal / secondary
  • Carcinoma, Ductal / therapy*
  • Combined Modality Therapy
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Docetaxel
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Genes, erbB-2 / genetics*
  • Humans
  • Liver Neoplasms / genetics
  • Liver Neoplasms / secondary
  • Middle Aged
  • Remission Induction
  • Taxoids / administration & dosage
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Taxoids
  • Deoxycytidine
  • Docetaxel
  • Capecitabine
  • Trastuzumab
  • Fluorouracil